Study Watch with Irregular Pulse Monitor (Home) vs AVIEW

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Study Watch with Irregular Pulse Monitor (Home)

by Verily Health

AVIEW

by Coreline Soft Co.

AI Verdict

Tool A is a wearable device designed for continuous physiological monitoring, focusing on irregular pulse detection and ECG measurements for conditions like AFib. In contrast, Tool B is an AI platform that analyzes CT scans to aid in the diagnosis and monitoring of lung diseases and coronary artery calcification. While both tools have applications in cardiology, their methodologies (wearable sensors vs. medical image analysis) and primary use cases are distinct.

Choose Study Watch with Irregular Pulse Monitor (Home) if…

Choose the Verily Study Watch with Irregular Pulse Monitor if your clinical practice or research requires continuous, unobtrusive physiological data collection from patients in a home setting, particularly for long-term irregular pulse monitoring and AFib detection. This prescription-only wearable is ideal for gathering real-world ECG and other biometric data to support remote patient management or large-scale clinical studies.

View Study Watch with Irregular Pulse Monitor (Home) →

Choose AVIEW if…

Choose AVIEW if your radiology department or cardiology practice needs an AI-driven platform to enhance the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans. This solution is best suited for improving diagnostic precision, automating measurements like lung nodule characterization and CAC scoring, and streamlining workflows for thoracic and cardiac imaging.

View AVIEW →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Study Watch with Irregular Pulse Monitor (Home)	AVIEW
Pricing	Unknown	Subscription; one-off payment
Deployment	Unknown	Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker)
FDA Status	Unknown	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AVIEW

Tool B (AVIEW) demonstrates superior usability for its target professional users by optimizing UI/UX for radiologists, streamlining complex workflows, and integrating with existing PACS/RIS/CIS systems. Clinical validation shows it significantly reduces case throughput and interpretation time, directly enhancing the user experience in a clinical setting.

Clinical Value

AVIEW

Tool B (AVIEW) offers extensive clinical validation in large-scale screening programs across multiple countries for lung cancer, COPD, and coronary artery calcification. Studies indicate it achieves a 100% detection rate for certain cancers and can outperform human radiologists in specific diagnostic tasks, leading to measurable improvements in diagnostic accuracy and efficiency.

Pricing & Value

AVIEW

Tool B (AVIEW) provides a more transparent and flexible pricing model, offering both subscription and one-off payment options based on installations and users. Tool A's pricing is not publicly available and requires direct contact, making it difficult to assess its value proposition.

Enterprise Readiness

AVIEW

Tool B (AVIEW) offers greater enterprise readiness with flexible deployment options (cloud, hybrid, local, virtualized) and explicit integration with standard healthcare IT systems like PACS/RIS/CIS. It has proven adoption in major U.S. medical centers and European national screening programs, and is validated against standards like IHE and FHIR.

Innovation

AVIEW

While both are innovative, Tool B (AVIEW) demonstrates a broader and more impactful application of AI in complex medical imaging diagnostics. It consolidates multi-disease CT assessment into a single, automated workflow, significantly reducing interpretation time and enabling it to serve as a 'first reader' in lung cancer screening, representing a significant leap in diagnostic AI.

Support & Docs

AVIEW

Tool B (AVIEW) provides a dedicated customer service email and lists various technical catalogs and brochures on its website, indicating a more structured approach to support and documentation. Tool A mentions a user manual and general contact information but lacks specific details on support channels or comprehensive documentation.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Study Watch with Irregular Pulse Monitor (Home)	AVIEW
Product Name	Study Watch with Irregular Pulse Monitor (Home)	AVIEW
Company	Verily Life Sciences LLC	Coreline Soft Co.
Primary Use Case	Prescription-only wearable device for clinical research and healthcare use, designed to unobtrusively collect physiological data, including ECG and irregular pulse monitoring.	AI platform offering comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans.
Target Specialties	Cardiology, Family Medicine, Internal Medicine	Cardiology, Pulmonology, Radiology
Core Technology/Data Type	On-demand single-channel ECG measurement, irregular pulse monitoring for atrial fibrillation (AFib) detection, multiple physiological sensors.	AI-powered lung nodule detection and characterization, emphysema quantification, coronary artery calcium (CAC) scoring from CT scans.

Videos

Demos, reviews, and walkthroughs featuring Study Watch with Irregular Pulse Monitor (Home) and AVIEW.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows for data acquisition and physician review?

The Verily Study Watch is a wearable device that unobtrusively collects physiological data, with cloud-based processing for physician review, aiming to create a clinical solution that considers clinician workflows and patient experience. AVIEW integrates with PACS/RIS/CIS, automating the analysis of CT scans and generating comprehensive reports directly within the radiology workflow, with a 'zero-click' experience for radiologists.

What specific clinical insights and accuracy levels can physicians expect from each tool's core functionalities?

The Verily Study Watch provides on-demand single-channel ECG measurements and irregular pulse monitoring for AFib detection, leveraging proprietary algorithms and machine learning, and has shown high accuracy in identifying atrial fibrillation. AVIEW offers AI-powered lung nodule detection with Lung-RADS scoring, emphysema quantification, and coronary artery calcium scoring (Agatston, volume, mass) from CT scans, with its CAC software yielding 99.2% accuracy for categorizing risk in a population study.

What is the expected learning curve for physicians to effectively utilize and interpret the data or analyses provided by each tool?

For the Verily Study Watch, physicians would primarily need to learn to interpret the physiological data and irregular pulse alerts generated from the wearable device, which is designed to be easy for patients to use. AVIEW requires radiologists to integrate AI-generated reports and 3D visualizations into their reading workflow, understanding new metrics like LAA analysis and various CAC scores, but aims to streamline and automate the process.

What considerations should a multi-site healthcare system take into account when planning to deploy either of these solutions?

Deploying the Verily Study Watch involves distributing prescription-only wearable devices and managing cloud-based data across multiple sites, with capabilities for global deployment. AVIEW offers flexible deployment options, including cloud-based, hybrid, or locally on dedicated hardware or virtualized environments, which can accommodate diverse multi-site IT infrastructures and has been adopted in multi-site screening programs in Europe and the U.S..

How quickly can a practice expect to see clinical value or workflow improvements after implementing each tool?

The Verily Study Watch can provide immediate value through continuous physiological data collection and early detection of irregular pulses for AFib, aiming to improve screening, diagnosis, and management of patients. AVIEW aims to deliver value by streamlining radiology workflows and enhancing diagnostic precision for lung cancer, COPD, and CAC, with clinical validation showing up to 89% faster case throughput and 60% reduction in interpretation time.

Given their distinct functionalities, in which specific clinical scenarios or specialties would each tool provide the most significant benefit?

The Verily Study Watch would provide significant benefit in cardiology, family medicine, and internal medicine for remote cardiac monitoring, AFib detection, and continuous physiological data collection, particularly for patients diagnosed with or susceptible to AFib. AVIEW is highly beneficial in radiology, pulmonology, and cardiology for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans, offering comprehensive imaging analysis and reporting.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Study Watch with Irregular Pulse Monitor (Home) or AVIEW

Backers

Who funded each tool's parent company.